

Tuesday, May 17, 2022

9:00 am - 12:00 pm **ProteoCure Management Committee meeting (Management Committee and Core Group members only)**

10 - 12:30 pm **Participants arrival and registration**

12:45 - 1:00 pm **Welcome message** (*Olivier Coux and Rosa Farràs*)

1:00 - 3:30 pm	Session 1: Proteostasis in acute and chronic disease (<i>Chairs: Christian Gaiddon and Niki Chondrogianni</i>)
1:00 - 1:30	NEURONS UNDER STRESS: CELL TYPE-SPECIFIC PROTEOSTATIC RESPONSES IN NEURODEGENERATIVE DISEASES
Keynote lecture	Wiep Scheper (<i>C. for Neurogenomics& Cognitive Research, NL</i>)
1:30 - 1:45	Kristina Tar: The diverse functions of the proteasome activator PA200 to maintain cellular quality control
1:45 - 2:00	Carina Holmberg-Still: Genetic proteasome regulators in health and aging-related disorders
2:00 - 2:15	Ulrike Topf: The role of the molecular co-chaperone prefoldin in maintenance of proteostasis
2:15 - 2:30	Carlos Pipaón González: Role of ubiquitin-like modifications in the physiopathology of Chronic Lymphocytic Leukemia
2:30 - 2:45	Joan Sala-Gaston: The ubiquitin ligase HERC2 regulates C-RAF/MKK3/p38 signalling pathway modulating the cellular oxidative stress response
2:45 - 3:00	Rupert Ecker: Contextual tissue cytometry using precision microscopy with artificial intelligence
3:00 - 3:15	Gilles Lalmanach: Cysteine cathepsins: regulation of their proteolytic balance in pulmonary fibrosis and COPD
3:15 - 3:30	Lydie Combaret: Getting inspired by the wild to elucidate mechanisms of resistance to skeletal muscle atrophy: role of the BMP/TGFβ balance

3:30 - 4:00 pm **Coffee break**

4:00 - 6:30 pm	Session 2: Drugging Proteostasis with small molecules or bioactive compounds (<i>Chairs: Regina Menezes and Elah Pick</i>)
4:00 - 4:30	IN SEARCH OF THE RIGHT TARGETS: HOW CAN WE DEFINE PROTEASE BIOLOGICAL SUBSTRATES
Keynote lecture	Oded Kleinfeld (<i>Technion, IL</i>)
4:30 - 4:45	Joana Isabel Gomes Neto: The deubiquitylase USP31 controls Chromosomal Passenger Complex stability and choreography
4:45 - 5:00	Marie-Pierre Bousquet: Dissecting proteasome diversity using Mass Spectrometry as a swiss army knife - a new target for drugging proteasome activity?
5:00 - 5:15	John Christianson: Targeting ubiquitination machinery at the endoplasmic reticulum
5:15 - 5:30	Germana Meroni: TRIM E3 ubiquitin ligases in rare genetic diseases
5:30 - 5:45	Emmanuelle Liaudet-Coopman: Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
5:45 - 6:00	Robin Ketteler: Inhibition of USP30 enhances mitophagy in models of Parkinson's disease
6:00 - 6:15	Guillaume Bossis: Targeting SUMOylation improves Acute Myeloid Leukemias response to treatments
6:15 - 6:30	Yilmaz Sinem: The proteasome activator function of cycloastragenol is dependent on the NRF-2 mediated induction of telomerase activity

6:30 - 7:30 pm **Speed presentations : one slide, 3 min., no questions** (*Chair: Makis Skoulakis*)

Wednesday, May 18, 2022

9:00 - 10:15 am	Session 3: Targeted proteolysis (roles, mechanism and players) (<i>Chairs: Rosa Barrio and Michael Glickman</i>)
9:00 - 9:30	PROXIDRUGS: NEW THERAPEUTICS FOR MULTIPLE DISEASES
Keynote lecture	Ivan Dikic (<i>Goethe University Frankfurt, DE</i>)
9:30 - 9:45	Carmen Rivas: Ubiquitin Like proteins in Viral Host Response
9:45 - 10:00	Andreas Bachmair: targeted proteolysis pathways that employ N-terminal degradation signals relevant for UPP and autophagy
10:00 - 10:15	Sabine Schipper-Krom: Screening platform to identify mutant huntingtin lowering genes and compounds

10:15 - 10:45 am **Coffee break**

10:45 - 11:00	Alfred Vertegaal: The Proteomics landscape of SUMO
11:00 - 11:15	Simona Polo: Hecw controls oogenesis and neuronal homeostasis by promoting the liquid state of ribonucleoprotein particles
11:15 - 11:30	Tommer Ravid: Conserved degronome features governing quality control-associated proteolysis
11:30 - 11:45	Georgia Chachami: Interplay between sumoylation and transcriptional regulation in the cellular response to hypoxia
11:45 - 12:00	James Sutherland: Biotin proteomics Identification of ubiquitin-like-dependent interactors using biotin-based proximity proteomics

12:00 - 1:00 pm **Standing lunch & poster session**

1:00 - 3:30 pm	Session 4: Proteostasis at the interface between discovery science, the clinic and pharma (<i>Chairs: Colin Adrain and Klaudia Brix</i>)
1:00 - 1:30	USING ARTIFICIAL INTELLIGENCE TO DISCOVER, OPTIMIZE AND VALIDATE TARGETED PROTEIN DEGRADERS - THE CURRENT STATE OF WHAT'S POSSIBLE
Keynote lecture	Nik Subramanian (<i>Kantify, BE</i>)
1:30 - 1:45	Dan Longley: Development and clinical positioning of a USP7 inhibitor - online conference
1:45 - 2:00	Sandra Kumper: Strategies to identify novel E3 Ligases for TPD - online conference
2:00 - 2:15	Lara Cantarero: Mitochondrial membrane contact sites and autophagy in axonopathy
2:15 - 2:30	Elah Pick: Interplay between NEDD8 pathways and the cellular redox state
2:30 - 2:45	Laura Sánchez-Bellver: USP48 as a new candidate gene for retinal ciliopathies
2:45 - 3:00	Kvido Stříšovský: Intramembrane proteolysis, cellular signaling and membrane protein quality control
3:00 - 3:15	Jyotsna Batra: Effects of genetic variation on functionality of Kallikrein 3 (PSA) in prostate cancer
3:15 - 3:30	Gustavo J. Gutierrez: Developing Targeted Protein Degradation modalities in biotech/pharmas

3:30 - 4:00 pm **Coffee break**

4:00 - 5:00 pm **Speed presentations one slide, 3 min., no questions** (*Chair: Marina Klemenčič*)

5:00 - 6:00 pm	Plenary lecture (<i>Chairs: Rosa Farràs and Olivier Coux</i>)
	CYSTEINE CATHEPSINS: GOOD, BAD AND NOT UGLY
	Boris Turk (<i>Ljubljana, SI</i>)

6:00 - 6:30 pm **Conclusions**

20:00 - ... **Gala dinner**

Thursday, May 19, 2022

9:00 - 10:15 am **Working groups: what has been done and what should be done ?** (*Chairs: Christine Blattner and Manuel Rodriguez*)

10:15 - 10:45 am **Coffee break**

10:15 am - 12:00 pm **Working groups: what has been done and what should be done ?** (*Chairs: Christine Blattner and Manuel Rodriguez*)